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OBJECTIVE: The LIFE Study demonstrated a signiﬁcant
reduction in cardiovascular morbidity and mortality in
hypertensive patients with ECG left ventricular hypertro-
phy treated with losartan (versus treatment with atenolol)
over a mean period of 4.8 years. This reduction was
essentially related to a signiﬁcant 25% decrease (p =
0.001) in the risk of fatal and non-fatal stroke. The objec-
tive of this study was to compare the treatment costs
relating to each therapeutic strategy throughout the dura-
tion of the LIFE Study. METHODS: Data on efﬁcacy and
resources consumed were extracted from the published
results of the LIFE study. A cost minimization study was
carried out and the costs were calculated from the point
of view of the French Health care system. The total esti-
mated direct costs included those relating to the medici-
nal product and management of the cardiovascular events
(myocardial infarction, angina pectoris, heart failure,
stroke and revascularization). The medicinal products
were valued on the basis of the purchasing price (retail
price inc. VAT), and hospitalization costs were estimated
on the basis of PMSI data and the national cost scale.
Indirect costs were not considered. RESULTS: Over the
4.8 years, the mean cost of losartan per patient ranged
from €1132 (lower bound) to €1199 (upper bound). The
mean cost of atenolol per patient was €366. The mean
cost of the cardiovascular events were respectively €1969
and €2261 for losartan and atenolol groups. Therefore,
the total mean cost per patient ranged from €3101 to
€3169 for the losartan group and was estimated €2627
for the atenolol group. CONCLUSION: The annual
incremental cost for each patient treated with losartan
ranged from €99 to €113. This additional cost is associ-
ated with a signiﬁcant reduction in cardiovascular mor-
bidity and mortality (especially stroke).
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OBJECTIVES: Rosuvastatin (Crestor®) is a new statin
with proven efﬁcacy for reducing plasma low-density
lipoprotein cholesterol (LDL-C) levels. A model has been
developed to estimate the budget impact and incremental
cost-effectiveness of rosuvastatin compared with other
statins for reducing LDL-C levels and treating patients to
goal. METHODS: The model considered the treatment
of an adult population with hypercholesterolaemia over
a 1-year period from the perspective of the UK primary
Health care provider. The clinical beneﬁt was a simulated
estimate of the proportion of the population attaining 
the European Atherosclerosis Society (EAS) guideline 
goal LDL-C plasma level (<3mmol/L). The model com-
pared the cost of statin treatment using current prescrib-
ing patterns with a scenario in which 30% of patients
currently receiving statins are switched to rosuvastatin.
Patients are switched from existing products according 
to market share. Sensitivity analyses varied the potential
prescribing share of rosuvastatin. RESULTS: Following
rosuvastatin introduction, the anticipated cost saving 
for a population of 1,000 patients would be £8,052
(€12,849) per year, with an additional 103 patients reach-
ing the EAS goal LDL-C level. Assuming a ﬁxed budget,
the introduction of rosuvastatin would allow an addi-
tional 30 patients to be treated with rosuvastatin, with a
total 132 extra patients achieving the goal. The analysis
showed that rosuvastatin is cost-effective compared 
with atorvastatin, pravastatin and simvastatin. Sensitivity
analyses showed that the results were robust to changes
in the prescribing share of rosuvastatin. CONCLUSION:
The introduction of rosuvastatin into primary care pre-
scribing should enable more patients to be treated with a
statin than is currently possible, and more patients would
reach EAS goal LDL-C levels. Compared with other cur-
rently available statins, prescribing rosuvastatin would
allow resources to be used more efﬁciently. The model can
be adapted for any European country to determine the
cost-effectiveness and potential budget impact of a new
statin.
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OBJECTIVE: Evidence-based medicine guidelines based
on venographic end points recommend extended venous
thromboembolism (VTE) prophylaxis with low-
molecular-weight heparin (LMWH) in patients having
elective hip surgery. The aim of the study was to estimate
the expected cost-effectiveness of such prophylaxis with
enoxaparin administered for 21 days postdischarge 
vs. using enoxaparin for hospital admission only.
METHODS: Decision analysis model was developed to
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combine probability data estimated from published liter-
ature and Polish data on resource use and unit cost.
Target population was people aged 70.58% women. The
perspective of Health care payer’s was adopted and only
direct medical costs were analysed. The outcome mea-
sures were life years gained (LYG), calculated on the basis
of available evidence for a preventive effect of enoxaparin
on VTE risk after elective hip replacement. Incremental
cost-effectiveness ratio was calculated to provide esti-
mates of the cost per life year gained. The cost-
effectiveness threshold was calculated on the basis of 
1-year haemodialysis treatment cost (60,000 PLN, €1 =
4 PLN; in 2003). The one-way and scenario sensitivity
analyses were performed. RESULTS: For hypothetical
cohort of 100 patient undergoing elective hip replacement
the expected cost and outcome were 53,470 PLN and
1269.4 LY for extended and 33,190 PLN and 1248.2 LY
for standard enoxaparin as prophylaxis for VTE. For 
the extended enoxaparin group this translated to 952
PLN/LYG. A series of one-way and scenario analyses
showed modest change in cost/LYG. In no instance did
the ICER exceed 3000 PLN/LYG. CONCLUSION:
Prolonged enoxaparin prophylaxis after elective hip
replacement is more effective than conventional short-
term prophylaxis in terms of LYG and also appears to be
clearly cost-effective, using Polish cost data.
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OBJECTIVES: To analyze and compare medium and
long-term clinical and economic outcomes of fonda-
parinux and enoxaparin in the prevention of venous
thromboembolism (VTE) after major orthopaedic surgery
(MOS) in Spain. METHODS: A decision-analytic model
was adapted to determine the incidence and cost conse-
quences of VTE-related events (deep vein thrombosis—
DVT, pulmonar embolism—PE, and post-thrombotic
syndrome—PTS) and major bleedings due to their pro-
phylaxis and treatment, in 2 hypothetic cohorts of 10,000
MOS patients each who had received either 8 injections
of enoxaparin or 7 injections of fondaparinux. Clinical
outcomes and their direct cost consequences for the
National Health System were calculated for different time
horizons (1 month, 3 months, 1 year, and 5 years after
surgery). Clinical input data were retrieved from pub-
lished clinical trials and epidemiological studies. Resource
use in the prophylaxis and management of all events was
determined by an international expert panel using the
Delphi technique and was validated for Spain by a local
VTE expert. Unit costs of the resources were extracted
from local databases and were expressed in Euros of
2002. Costs were discounted at 3% per year. RESULTS:
Five years after surgery mortality caused by PE was 46%
less in the fondaparinux cohort, while mortality due to
major bleedings following prophylaxis or treatment of
VTE did not differ between cohorts. The accumulated
number of cases of DVT, PE, and PTS were, respectively,
33%, 46%, and 26% less. Additional drug cost with 
fondaparinux amounted to €14,582 per life saved. 
From three months after surgery onwards the price 
differential was compensated by savings that resulted 
from the avoidance of VTE-related events. CONCLU-
SIONS: Prophylaxis with fondaparinux vs. enoxaparin
considerably reduces the number of fatalities and other
VTE-related events after MOS and leads to net savings
for the National Health System in the medium and long
term.
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OBJECTIVES: The CURE study has demonstrated that
clopidogrel on top of standard therapy (including aspirin,
ASA) decreases the risk of cardiovascular death, myocar-
dial infarction and stroke by 20% in patients with acute
coronary syndromes without ST- elevation. The objective
of this study was to evaluate the cost-effectiveness of
adding clopidogrel to standard treatment in the Nether-
lands. METHODS: The cost-effectiveness, in terms of
costs per saved life-year, was determined with a Markov
model in which patients were divided according to vas-
cular events and time from last event. Effectiveness data
were derived from the CURE study; long-term outcomes
were based on epidemiological estimates concerning age
speciﬁc event rates and case fatality rates. Quality of life
estimates were obtained from the literature. Direct costs
were updated from previous studies, indirect costs were
disregarded due to the age of the patients. RESULTS: The
number needed to treat with clopidogrel for one year to
prevent one event was 35. The annual cost of treatment
was €20.355 in patients treated with clopidogrel on top
of standard therapy (including ASA) and €20.342 in
patients in the control group (standard therapy including
ASA). After discounting costs and effects at 4%, treat-
ment with clopidogrel resulted in annual cost saving of
€17 per patient. There was also a gain in life-years and
quality adjusted life years (QUALY’s) of 0.122 year and
0.137 QALY’s per patient. Multivariate sensitivity analy-
ses revealed that the results are robust. CONCLUSIONS:
Clopidogrel is highly cost-effective when added to stan-
